CDx Diagnostics presented Wide Area Transepithelial Sampling with 3D Tissue Analysis data showing crypt dysplasia played a role in high-grade esophageal dysplasia and esophageal cancer at ACG 18, Oct. 5-10 in Philadelphia.
Here's what you should know:
1. WATS3D successfully detected crypt dysplasia. Physicians cannot detect crypt dysplasia with conventional biopsies.
2. Chapel Hill-based University of North Carolina gastroenterologist Nicholas Shaheen, MD, said, "The data reported today suggest that samples obtained and analyzed with WATS3D allow detection of this condition. Most importantly, the data also suggest that crypt dysplasia is something we should wish to detect, because it has a higher risk of progression to high-grade dysplasia or esophageal cancer compared to non-dysplastic Barrett's."
3. Researchers conducted a study of 4,512 patients who had two WATS3D assessments six months apart. About 4,409 patients had non-dysplastic Barrett's esophagus at baseline. They were followed for 1.4 years on average between assessments. An additional 380 non-dysplastic Barrett's esophagus -patients were followed for 1.25 years between assessments.
4. Of the 1.4-year patients, 19 progressed to high-grade dysplasia or esophageal adenocarcinoma. Of the 1.25-year non-dysplastic Barrett's esophagus patients, 10 progressed to high-grade dysplasia or esophageal adenocarcinoma. Progression rate from WATS3D-determined crypt dysplasia was 9.9 percent per patient year, a calculation based on the number of patients with each histology type.
5. CDx Diagnostic CEO and Founder Mark Rutenberg said, "We believe [this] data highlight how WATS3D provides physicians and patients with accurate and critical information that can inform the management of Barrett's esophagus and help preempt esophageal cancer."